Almon Therapeutics

Almon Therapeutics is a clinical-stage biotechnology company focused on developing small molecule therapies for metabolic and liver diseases. The company's primary focus is on metabolic dysfunction-associated steatohepatitis (MASH), a condition characterized by liver inflammation and fat accumulation. Its lead candidate, ALM-001, is a liver-selective thyroid hormone receptor beta (THR-beta) agonist designed to improve hepatic metabolism while avoiding the systemic side effects typically associated with thyroid hormone activation. By specifically targeting the beta isoform in the liver, Almon aims to provide a safer and more effective treatment option for patients with chronic liver disease. The company is headquartered in San Diego and led by a management team with extensive experience in the metabolic disease space.